Cargando…

Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting

The gut microbiome has shown promise as a predictive biomarker for various diseases. However, the potential of gut microbiota for prospective risk prediction of liver disease has not been assessed. Here, we utilized shallow shotgun metagenomic sequencing of a large population-based cohort (N > 7,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Méric, Guillaume, Havulinna, Aki S., Teo, Shu Mei, Åberg, Fredrik, Ruuskanen, Matti, Sanders, Jon, Zhu, Qiyun, Tripathi, Anupriya, Verspoor, Karin, Cheng, Susan, Jain, Mohit, Jousilahti, Pekka, Vázquez-Baeza, Yoshiki, Loomba, Rohit, Lahti, Leo, Niiranen, Teemu, Salomaa, Veikko, Knight, Rob, Inouye, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097589/
https://www.ncbi.nlm.nih.gov/pubmed/35354069
http://dx.doi.org/10.1016/j.cmet.2022.03.002
Descripción
Sumario:The gut microbiome has shown promise as a predictive biomarker for various diseases. However, the potential of gut microbiota for prospective risk prediction of liver disease has not been assessed. Here, we utilized shallow shotgun metagenomic sequencing of a large population-based cohort (N > 7,000) with ∼15 years of follow-up in combination with machine learning to investigate the predictive capacity of gut microbial predictors individually and in conjunction with conventional risk factors for incident liver disease. Separately, conventional and microbial factors showed comparable predictive capacity. However, microbiome augmentation of conventional risk factors using machine learning significantly improved the performance. Similarly, disease-free survival analysis showed significantly improved stratification using microbiome-augmented models. Investigation of predictive microbial signatures revealed previously unknown taxa for liver disease, as well as those previously associated with hepatic function and disease. This study supports the potential clinical validity of gut metagenomic sequencing to complement conventional risk factors for prediction of liver diseases.